新冠口服药莫努匹韦最新研究结果：早期治疗可显著降低住院和死亡风险

Molnupiravir (Lagevrio) is an oral antiviral medicine indicated for the treatment of adults with mild to moderate COVID-19 who test positive for the SARS-COV-2 virus and have at least one risk factor for progression to severe disease.

In the UK, Molnupiravir is the first oral antiviral drug authorized to treat adult patients with mild to moderate COVID-19 who have a positive diagnostic test for the SARS-CoV-2 virus and at least one risk factor for progression to severe disease. The European Medicines Agency (EMA) issued a positive scientific opinion on molnupiravir in accordance with Article 5.3 of Regulation No. 726/2004, with the aim of making decisions on the use of molnupiravir before national approval for marketing. Regulatory applications are under review or pending, including Emergency Use Authorization (EUA) applications from the U.S. Food and Drug Administration (FDA) and the Japanese Ministry of Health, Labor and Welfare.

Dean Y., president of Merck Research Laboratories Dr. Li said: "In the MOVe-OUT trial, molnupiravir significantly reduced the risk of hospitalization and death in a diverse group of people at risk for more severe COVID-19. The number of COVID-19 cases, hospitalizations and deaths reported globally continues to increase, reminding us that new treatments are urgently needed, which is why we are accelerating and rigorously pursuing authorization to allow global collaboration Eligible patients were treated with molnupiravir more quickly. Importantly, the efficacy we observed in patients with more common variants was consistent, and recent preclinical evidence suggests that molnupiravir has antiviral activity against Omicron, a finding that is encouraging given the uncertainty about the future evolution of the SARS-CoV-2 virus."

Wendy, CEO of Ridgeback Biotherapeutics "These positive results published in the New England Journal of Medicine suggest that molnupiravir, studied as a single agent that can be taken at home (regardless of food intake, with no known drug interactions and without the need for dose adjustments in patients with renal or hepatic impairment), has the potential to be a valuable addition to COVID-19 treatment options," said Holman. "We thank the clinical trial participants and investigators for their efforts and will continue to study molnupiravir for the treatment and prevention of COVID-19."

References:

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study.html